<DOC>
	<DOCNO>NCT01915823</DOCNO>
	<brief_summary>The purpose study determine Dymista nasal spray well safer placebo treat child age 4 &lt; 12 year old seasonal allergic rhinitis .</brief_summary>
	<brief_title>Safety Efficacy Trial Dymista Nasal Spray Children Ages 4 11 With Seasonal Allergic Rhinitis ( SAR )</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis , Allergic , Seasonal</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>Male female subject age &gt; 4 year &lt; 12 year age , inclusive screen visit The parent/caregiver must provide write informed consent child must provide pediatric assent , possible Willing able comply study requirement Have history seasonal allergic rhinitis ( SAR ) pollen prevail allergy season . The presence immunoglobulin E ( IgE ) mediate hypersensitivity prevailing pollen , confirm positive response skin prick test . A histamine skin test must also positive . A positive response pollen skin test histamine skin test define wheal diameter least 4 mm large negative saline control General good health free disease concomitant treatment could interfere interpretation study result determine investigator sponsor 's medical officer On first day placebo leadin period ( Visit 1 ) subject must 12hour reflective total nasal symptom score ( rTNSS ) ≥6 reflective congestion score ≥2 qualify entry . At Visit 2 : Have take least 6 dos placebo leadin medication placebo leadin period At Visit 2 , eligible entry doubleblind treatment period , subject must total seven leadin symptom assessment past 3 day leadin period include Day Randomization ( Visit 2 , Day 1 ) : 12hour reflective TNSS ≥ 42 12hour reflective congestion score ≥14 On nasal examination , presence superficial moderate nasal mucosal erosion , nasal mucosal ulceration , nasal septum perforation ( Grade 1B 4 ) either screen visit randomization visit Nasal disease ( ) likely affect deposition intranasal medication , acute chronic sinusitis , rhinitis medicamentosa , clinically significant polyposis , clinically significant nasal structural abnormality . Nasal surgery sinus surgery within previous year . The use investigational drug within 30 day prior sign inform consent/pediatric assent Visit 1 . No investigational product permit use conduct study Presence hypersensitivity azelastine hydrochloride and/or fluticasone propionate drug similar azelastine hydrochloride and/or fluticasone propionate Respiratory tract infection within 14 day prior Visit1 Significant pulmonary disease include asthma . Subjects intermittent asthma require shortacting inhaled bronchodilator ( often twice per week ) nocturnal awaken result asthma eligible enrollment Chronic obstructive sleep apnea syndrome ( clinical diagnosis ) Existence surgical medical condition , opinion investigator sponsor 's medical monitor , might significantly alter absorption , distribution , metabolism , excretion study drug might significantly affect subject 's ability complete trial Clinically relevant abnormal physical finding , opinion investigator sponsor 's medical monitor , would interfere objective study may preclude compliance study procedure Family member research center private practice personnel directly involve study exclude Members household enrol time Subjects use medication therapy could interfere safety efficacy evaluation proper washouts medication therapy Any behavioral condition could affect subject 's ability accurately report symptom caregiver developmental delay , attention deficit disorder , autism Positive pregnancy test female subject ≥ 9 year age Females pregnant nursing Females childbearing potential abstinent practice medically acceptable method contraception Subjects fail complete symptom diary leadin period , define miss data &gt; 50 % entry Subjects receive immunotherapy injection ( antigen desensitization ) must stable maintenance regimen least 30 day first study visit ( adjustment regimens follow brief period miss injection preclude participation ) . Dose reduction new bottle use preclude participation . Planned travel outside pollen area study period</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>